Vanucizumab Explained

Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.^{[1] [2]}

Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.

This drug was developed by Genentech/Roche.

References

1. http://www.ama-assn.org/resources/doc/usan/x-pub/vanucizumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab
2. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 . WHO Drug Information . 28 . 2 . 2014 .